October 10, 2016 Columns by Debi Wilson Is Your MS Rocking Out on Heavy Metals? The jury is still out on the role, if any, that heavy metals play in multiple sclerosis. Many theories have been floating around for years regarding the possible connection between MS and dental amalgams, pesticides, additives to food, lead paint in older homes … and the list goes on. The National…
June 30, 2016 Columns by admin To Fight MS, Drink Four Cups of Coffee a Day? Ready to fight MS? Well, you can start first thing every day. So, how do you start your day — a coffee maybe, or a great cup of tea? Tea is my choice but I also enjoy a magnificent cup of Spanish coffee. According to a number of recent studies, coffee and…
June 17, 2016 News by Patricia Silva, PhD Adamas Reports Positive Results in Study of Drug to Treat MS Patients with Walking Difficulties Adamas Pharmaceuticals recently reported positive results from its Phase 2 proof-of-concept clinical trial evaluating ADS-5102 (amantadine HCl), an extended-release version of amantadine, in multiple sclerosis (MS) patients with difficulties in walking. The trial (NCT02471222), a double-blind, placebo-controlled and two-arm parallel group study, evaluated ADS-5102 given once daily at 340 mg, at bedtime, for four…
November 18, 2014 News by Patricia Silva, PhD Home Exterior Company Remodels and Repairs MS Patient’s Home for Free For those with Multiple Sclerosis, the progressive manner in which the disease slowly deteriorates motor function, balance, and coordination can make home maintenance an impossibility. Add to this the well-documented issues that MS patients have with finding and keeping jobs and very quickly the cost and effort to maintain…
November 17, 2014 News by Charles Moore Genzyme’s Lemtrada Approved by the FDA Cambridge, Massachusetts based Genzyme announced Friday that the U.S. Food and Drug Administration (FDA) has approved the company’s new drug Lemtrada (alemtuzumab) for treatment of people with relapsing forms of multiple sclerosis, which includes people who experience periodic MS attacks, such as those who have relapsing-remitting MS or secondary-progressive…
October 2, 2014 News by Charles Moore Québec Government Covers Lemtrada Second-line Treatment For Relapsing-remitting Multiple Sclerosis Genzyme, a Sanofi company, has announced that the Canadian province of Québec’s Institut national d’excellence en santé et services sociaux (INESSS) has recommended that the company’s multiple sclerosis (MS) drug Lemtrada (alemtuzumab) 12 mg be included on the provincial drug formulary under “Médicament d’exception” as a second-line treatment for…
September 16, 2014 News by Patricia Silva, PhD Fatigue Felt by MS Patients May Be From Underdiagnosed Sleep Disorders The underlying cause of fatigue experienced by multiple sclerosis (MS) patients may be undiagnosed sleep disorders, according to a study conducted at the Department of Neurology of the University of California. Not only is that a problem in itself, but also an undiagnosed and untreated sleeping disorder may exacerbate the…
June 16, 2014 News by Patricia Silva, PhD Researcher Recommends Brain Imaging To Treat MS-Related Depression Magnetic resonance imaging (MRI) can predict responses to depression treatment in patients with multiple sclerosis (MS), according to Anthony Feinstein, Professor at the Department of Psychiatry of the Sunnybrook Health Sciences Centre & the University of Toronto. In the presentation “Depression in MS: Is brain imaging helpful?” at this…
June 2, 2014 News by Charles Moore Genzyme Resubmits Multiple Sclerosis Drug Lemtrada For FDA sBLA Approval Review Cambridge, Mass. Based Genzyme, a Sanofi subsidiary, announced May 30 that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s resubmission of its supplemental Biologics License Application (sBLA) seeking approval of its proprietary drug Lemtrada (alemtuzumab) for treatment of relapsing forms of multiple sclerosis (MS).